Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.50 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.50 |
| ▸ | HCAR2 | Q8TDS4 | 7/20 | 0.46 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.36 |
| ▸ | GABRR2 | P28476 | 2/20 | 0.36 |
| ▸ | BLM | P54132 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | APEX1 | P27695 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL3088427 | 1.00 | TSHR (0.50) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL5792063 | 0.97 | TSHR (0.53) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL6826914 | 0.97 | TSHR (0.53) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Maleic Acid SCHEMBL28847233 | 0.94 | TSHR (0.50) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Crotonic Acid SCHEMBL27462229 | 0.84 | TSHR (0.38) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL6235895 | 0.80 | TSHR (0.53) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Maleic Acid SCHEMBL3176628 | 0.79 | TSHR (0.60) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL27710817 | 0.79 | TSHR (0.60) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL3176640 | 0.79 | TSHR (0.60) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL6095324 | 0.78 | TSHR (0.69) | TSHRTP53EGLN1EGLN3HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2097137-B1 | COMPOSITIONS COMPRISING STRONTIUM AND USES THEREOF IN THE TREATMENT OR PREVENTION OF GINGIVITIS, PERIODONTITIS, PERIODONTITIS AS A MANIFESTATION OF SYSTEMIC DISEASES, AND NECROTIZING PERIODONTAL DISEASES. | MOKWALO SPF S A (LU) | 2012-09-19 | — | — | EP | claimed |
| US-20100272802-A1 | COMPOSITIONS COMPRISING STRONTIUM AND USES THEREOF IN THE TREATMENT OR PREVENTION OF GINGIVITIS, PERIODONTITIS, PERIODONTITIS AS A MANIFESTATION OF SYSTEMIC DISEASES, AND NECROTIZING PERIODONTAL DISEASES | MOKWALO SPF S.A., LUXEMBOURG (LU) | 2010-10-28 | — | — | US | claimed |
| EP-2097137-A1 | COMPOSITIONS COMPRISING STRONTIUM AND USES THEREOF IN THE TREATMENT OR PREVENTION OF GINGIVITIS, PERIODONTITIS, PERIODONTITIS AS A MANIFESTATION OF SYSTEMIC DISEASES, AND NECROTIZING PERIODONTAL DISEASES. | Strontin APS (DK) | 2009-09-09 | — | — | EP | claimed |
| WO-2008061535-A1 | COMPOSITIONS COMPRISING STRONTIUM AND USES THEREOF IN THE TREATMENT OR PREVENTION OF GINGIVITIS, PERIODONTITIS, PERIODONTITIS AS A MANIFESTATION OF SYSTEMIC DISEASES, AND NECROTIZING PERIODONTAL DISEASES. | STRONTIN APS (DK) | 2008-05-29 | — | — | WO | claimed |
| US-20080026037-A1 | Compositions Comprising Strontium and Vitamin D and Uses Thereof | STRONTIN APS | 2008-01-31 | — | — | US | claimed |
| EP-1768748-A2 | COMPOSITIONS COMPRISING STRONTIUM AND VITAMIN D AND USES THEREOF | Strontin APS (DK) | 2007-04-04 | — | — | EP | claimed |
| WO-2006000224-A2 | COMPOSITIONS COMPRISING STRONTIUM AND VITAMIN D AND USES THEREOF | STRONTIN APS (DK) | 2006-01-05 | — | — | WO | claimed |
| US-20170157001-A1 | Compositions Comprising Strontium and Uses Thereof in the Treatment or Prevention of Gingivitis, Periodontitis, Periodontitis as a Manifestation of Systemic Diseases, and Necrotizing Periodontal Diseases | CHRISTENSEN JOHN NIKOLAJ (DK) | 2017-06-08 | — | — | US | disclosed |
| US-8658206-B2 | Compositions comprising strontium and vitamin D and uses thereof | Mokwalo SA (LU) | 2014-02-25 | — | — | US | disclosed |
| EP-2097137-B1 | COMPOSITIONS COMPRISING STRONTIUM AND USES THEREOF IN THE TREATMENT OR PREVENTION OF GINGIVITIS, PERIODONTITIS, PERIODONTITIS AS A MANIFESTATION OF SYSTEMIC DISEASES, AND NECROTIZING PERIODONTAL DISEASES. | MOKWALO SPF S A (LU) | 2012-09-19 | — | — | EP | disclosed |
| US-20100272802-A1 | COMPOSITIONS COMPRISING STRONTIUM AND USES THEREOF IN THE TREATMENT OR PREVENTION OF GINGIVITIS, PERIODONTITIS, PERIODONTITIS AS A MANIFESTATION OF SYSTEMIC DISEASES, AND NECROTIZING PERIODONTAL DISEASES | MOKWALO SPF S.A., LUXEMBOURG (LU) | 2010-10-28 | — | — | US | disclosed |
| EP-1768748-B1 | COMPOSITIONS COMPRISING STRONTIUM AND VITAMIN D AND USES THEREOF | STRONTIN APS (DK) | 2009-09-23 | — | — | EP | disclosed |
| EP-2097137-A1 | COMPOSITIONS COMPRISING STRONTIUM AND USES THEREOF IN THE TREATMENT OR PREVENTION OF GINGIVITIS, PERIODONTITIS, PERIODONTITIS AS A MANIFESTATION OF SYSTEMIC DISEASES, AND NECROTIZING PERIODONTAL DISEASES. | Strontin APS (DK) | 2009-09-09 | — | — | EP | disclosed |
| WO-2008061535-A1 | COMPOSITIONS COMPRISING STRONTIUM AND USES THEREOF IN THE TREATMENT OR PREVENTION OF GINGIVITIS, PERIODONTITIS, PERIODONTITIS AS A MANIFESTATION OF SYSTEMIC DISEASES, AND NECROTIZING PERIODONTAL DISEASES. | STRONTIN APS (DK) | 2008-05-29 | — | — | WO | disclosed |
| US-20080026037-A1 | Compositions Comprising Strontium and Vitamin D and Uses Thereof | STRONTIN APS | 2008-01-31 | — | — | US | disclosed |
| EP-1768748-A2 | COMPOSITIONS COMPRISING STRONTIUM AND VITAMIN D AND USES THEREOF | Strontin APS (DK) | 2007-04-04 | — | — | EP | disclosed |
| WO-2006000224-A2 | COMPOSITIONS COMPRISING STRONTIUM AND VITAMIN D AND USES THEREOF | STRONTIN APS (DK) | 2006-01-05 | — | — | WO | disclosed |